Presidio News

01.09.12
Presidio Pharmaceuticals Inc. Reports Progress with Hepatitis C Antiviral Programs

11.04.11
Presidio Pharmaceuticals Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Studies for its Second-Generation NS5A Inhibitor, PPI-668

10.25.11
Presidio Pharmaceuticals, Inc. Announces the Appointment of H.Daniel Perez, M.D. as President and Chief Executive Officer

03.30.11
Presidio Pharmaceuticals Announces Positive Results--Phase 1b Clinical Trial of PPI-461

10.27.10
Presidio Pharmaceuticals, Inc. to Present First Clinical Data for PPI-461, a New HCV NS5A Inhibitor, at the American Association for the Study of Liver Diseases (AASLD) Meeting

07.14.10
Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1a Clinical Trial of PPI-461, a Potent, New Hepatitis C Virus (HCV) Inhibitor

06.02.10
Pamela Vig Joins Presidio Pharmaceuticals, Inc. as Senior Director of Clinical Research

05.26.10
Presidio Pharmaceuticals, Inc. Selects Second Clinical Candidate from Hepatitis C Virus NS5A Inhibitor Program

04.27.10
Presidio Pharmaceuticals, Inc. Initiates First-in-Human Clinical Trial of PPI-461, an Investigational NS5A Inhibitor for HCV

03.30.10
Presidio Pharmaceuticals, Inc. to Present at the Canaccord Adams' Hepatitis C Conference

01.12.10
Eric Ruby Joins Presidio Pharmaceuticals, Inc. as Vice President of Regulatory Affairs

12.02.09
Tom Anderton Joins Presidio Pharmaceuticals, Inc. as Vice President of Intellectual Property and Legal Affairs

08.05.09
Dr. Nathaniel Brown Joins Presidio Pharmaceuticals, Inc. as Senior Vice President of Clinical Development

07.13.09
Presidio Pharmaceuticals, Inc. Gets $27 Million B-Extension for Preclinical HCV Programs

07.09.09
Presidio Pharmaceuticals, Inc. Raises $27 Million in Additional Financing

07.07.09
Presidio Pharmaceuticals, Inc. selects PPI-461 as a Clinical Candidate in their Hepatitis C Virus NS5A Program

04.16.09
Presidio to Present Data on HCV NS5A Inhibitor Program at EASL Conference

08.05.08
Presidio Pays Down Future XTL Milestone, Royalty, and Sublicense Payments

04.14.08
BioCentury Emerging Company Profile -  Presidio: Penultimate NRTIs

03.20.08
Presidio Obtains Rights to XTL Biopharmaceuticals' HCV NS5A Program

1.07.08
Leo Redmond Joins Presidio Pharmaceuticals as Chief Financial Officer

12.05.07
Presidio Relocates Headquarters to Mission Bay, San Francisco

09.18.07
Presidio Adds Industry Veteran Colonno as Chief Scientific Officer

08.29.07
Presidio Closes $26 Million Series B Financing